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Background: Caveolin-1 (CAV1) has been implicated both in tumor suppression and progression, whereby the
specific role appears to be context dependent. Endometrial cancer is one of the most common malignancies of the
female genital tract; however, little is known about the role of CAV1 in this disease.
Methods: Here, we first determined by immunohistochemistry CAV1 protein levels in normal proliferative human
endometrium and endometrial tumor samples. Then using two endometrial cancer cell lines (ECC: Ishikawa and
Hec-1A) we evaluated mRNA and protein levels of CAV1 by real time qPCR and Western blot analysis, respectively.
The role of CAV1 expression in ECC malignancy was further studied by either inducing its expression in endometrial
cancer cells with the tumor promotor 12-O-tetradecanoyl-phorbol-13-acetate (4β-TPA) or decreasing expression
using short-hairpin RNA constructs, and then evaluating the effects of these changes on ECC proliferation,
transmigration, matrigel invasion, and colony formation in soft agar.
Results: Immunohistochemical analysis of endometrial epithelia revealed that substantially higher levels of CAV1 were
present in endometrial tumors than the normal proliferative epithelium. Also, in Ishikawa and Hec-1A endometrial
cancer cells CAV1 expression was readily detectable. Upon treatment with 4β-TPA CAV1 levels increased and coincided
with augmented cell transmigration, matrigel invasion, as well as colony formation in soft agar. Reduction of CAV1
expression using short-hairpin RNA constructs ablated these effects in both cell types whether treated or not with
4β-TPA. Alternatively, CAV1 expression appeared not to modulate significantly proliferation of these cells.
Conclusion: Our study shows that elevated CAV1, observed in patients with endometrial cancer, is linked to enhanced
malignancy of endometrial cancer cells, as evidenced by increased migration, invasion and anchorage-independent
growth.
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Caveolin-1, a member of the caveolin family of proteins
composed of the isoforms caveolin-1, -2 and -3, has
been implicated in processes related to cell transform-
ation. Caveolin-1 and -2 are expressed in most tissues,
while caveolin-3 distribution is restricted to muscle and
glial cells [1, 2]. CAV1 is thought to function as a tumor* Correspondence: aquest@med.uchile.cl
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ternatively, CAV1 is upregulated in some metastatic [6–9]
and multidrug resistant cancer cells [6, 10, 11] where ex-
pression is associated with cell survival and proliferation
[10, 12, 13]. Thus, the role CAV1 plays in tumor develop-
ment and progression appears to be context dependent.
Endometrial adenocarcinoma is one of the most com-
mon malignancies of the female genital tract [14] and is
considered a very frequent tumor type in industrialized
countries [15]. Generally, little is known about CAV1 in
this type of cancer compared with others, like breast
cancer [16–20]. In cultured human endometrial cancerle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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during epithelial-mesenchymal transition (EMT) [21].
However, in a microarray study of type I endometrial
cancer biopsies, a decrease in CAV1 mRNA was re-
ported when compared with control samples [22]. Thus,
whether CAV1 is expressed and how the protein may
contribute to the development of endometrial cancer re-
mains an open question.
Phorbol esters are well-known tumor promotors and
activators of Protein Kinase Cs (PKCs) that may induce
profound alterations in proliferative responses in a cell-
type dependent manner [23]. Also effects appear to
depend on the degree of tumor progression. In the moder-
ately differentiated endometrial Hec-1A adenocarcinoma
cell line, significant increases in proliferation and morpho-
logical changes were observed in response to 4β −TPA,
while no such changes were reported for the well-
differentiated mixed mesodermal cell line SKUT-1-B [24].
On the other hand, 4β −TPA is a well-known activator of
PKCs, which in turn are implicated in regulating the ex-
pression of CAV1 [25]. However, to our knowledge, no re-
ports are available indicating how 4β −TPA affects CAV1
expression and whether this relates to tumor promotion
in endometrial cancer cells (ECC).
Here we examined the possibility that CAV1 might
contribute to the transformed phenotype of ECC. We
show that CAV1 was expressed at low levels in normal
proliferating endometrium, but was readily detectable in
endometrial samples of human adenocarcinomas of
tumor grades 1-3, as well as in ECC lines. The phorbol
ester 4β-TPA was employed as a generic tumor promo-
tor with the objective of establishing how increasing
CAV1 expression correlated with malignacy in these
cells. Specifically, we demonstrated that 4β −TPA aug-
mented CAV1 expression, as well as enhanced migration,
invasive capacity and anchorage-independent growth of
two ECC lines. Alternatively, down-regulation of CAV1
using specific short hairpin RNA (shRNA) constructs re-
duced these characteristics in the same cells. Taken to-
gether, these results implicate enhanced CAV1 expression
observed in endometrial adenocarcinomas and ECC lines




The following reagents and antibodies were purchased
from the sources indicated: 12-O-tetradecanoyl-phorbol-
13-acetate (4β-TPA) (Enzo, NY, USA), BCA protein assay
kit (Pierce, Rockford, USA), DMEM-F12 (Gibco-BRL, Pais-
ley, UK), Fetal bovine serum (Biological Industries, Kibbutz
Beit Haemek, Israel), Histostain-SP Broad Spectrum kit
(Invitrogen, Carlsbad, USA), Penicillin, Streptomycin
(Gibco-BRL, Paisley, UK), Puromycin (Sigma, USA),Superfect (Qiagen, Valencia, USA), Orthovanadate (Sigma,
USA), Antipain, Benzamidine, Leupeptin, Phenylmethyl-
sulphonylfluoride (Calbiochem, Germany), EZ-ECL
(Biological Industries, Kibbutz Beit Haemek, Israel),
RNAase-free DNAase (Promega, Madison, USA), TriZOL
(Invitrogen, Carlsbad, USA), M-MLV Reverse Transcript-
ase (Promega, Madison, USA), Brilliant II SYBR Green
Master Mix qPCR kit (Stratagene, USA), MTS® Prolifera-
tion Assay Kit (Promega, Madison, USA), low melting
point (l.m.p) agarose (Invitrogen, Carlsbad, USA), poly-
clonal antibodies anti-caveolin-1 (BD, NJ, USA), anti-β-
actin and anti-cytokeratin (Sigma, USA), monoclonal
antibody anti-caveolin-2 (Santa Cruz Biotechnology, CA,
USA), secondary antibody Goat anti-rabbit IgG coupled to
horseradish peroxidase (Chemicon-Millipore, Billerica,
USA).
Tissue collection
Normal endometrial samples were obtained with a
pipelle suction curette from the corpus of the uteri from
healthy women with secondary infertility who attended
the Infertility Clinic of the San Borja Arriarán Clinical
Hospital, School of Medicine, University of Chile
(Santiago, Chile). Biopsies were dated with the patient’s
last menstrual period and were histologically confirmed
using Noyes criteria [26]. Archival tissue blocks of endo-
metrial tissue were obtained from the Department of
Pathology of the San Borja Arriarán Clinical Hospital
and utilized for immunohistochemical analysis. Both
healthy and pathological subjects had not been exposed
to exogenous hormones for at least 3 months and soli-
cited medical assistance due to metrorrhagia, except for
those with infertility related problems. All endometrial
samples were classified by an experienced histopatholo-
gist. This study was approved by the ethics committee of
the San Borja Arriarán Clinical Hospital, School of
Medicine, University of Chile. All samples were obtained
with informed consent of the patients involved.
Tissue immunohistochemistry
CAV1 was detected by immunostaining of 5-μm sections
from formalin-fixed, paraffin-embedded endometrial bi-
opsies. Tissue sections were deparaffinized in xylene and
hydrated gradually in graded alcohol. The sections were
incubated in antigen retrieval solution (100 mM Tris
buffer, pH 9.5) at 100 °C for 20 min. Endogenous perox-
idase activity was eliminated by incubating the samples
in 0.2 % hydrogen peroxide in methanol for 30 min.
Non-specific antibody binding sites were blocked with
4 % PBS–BSA for 1 h. Primary anti-CAV1 antibodies
were applied to the samples and incubated overnight at
4 °C in a humidified chamber. Negative controls were
analyzed on adjacent sections incubated without primary
antibody and using non-immune mouse serum. The
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streptavidin–peroxidase system with 3, 3′diaminobenzi-
dine as the chromogen. Samples were counterstained
with hematoxylin. Immunochemical staining for CAV1
was quantified using the Image-Pro Plus v. 4.5.029 soft-
ware (Media Cybernetics, USA) and the Expression
Level Score (ELS) was defined as the Mean Density of
CAV1-specific staining/Area.
Cell culture
Ishikawa cells, originally from a 39-year-old woman,
were established as a well-differentiated endometrial
adenocarcinoma cell line [27]. Hec-1A cells were estab-
lished from a 71-year-old woman and are considered a
moderately differentiated cell line [28]. Thus, Ishikawa
and Hec-1A cells are cell lines characteristic of grade 1
and grade 2 endometrial tumors, respectively [29]. Ishi-
kawa and Hec-1A cells were cultured in DMEM-F12
supplemented with 10 % FBS and antibiotics (10 000 U/
ml penicillin, 10 μg/ml streptomycin) at 37 °C, 5 % CO2.
CAV1 shRNA lentiviral infection
Lentiviral transduction particles encoding for shRNA
against CAV1 (shCav-1 (#5)) and for luciferase (shLuc)
were obtained from the Broad Institute, Cambridge, USA.
HEK293T cells were transfected with plasmids for the vec-
tor (pLKO.1puro), packaging (Δ8.9–pCMVΔR8.9 and vsv-
g–pHCMV-G) and the corresponding shRNA against
CAV1 (shCav-1(#5)) and luciferase (shLuc). After 24 h
of transfection, using The Superfect® Reagent (Qiagen®,
Valencia, USA), supernatants were recovered, aliquoted
and stored frozen at -20 °C. The shRNA sequences tested
were: CGACGTGGTCAAGATTGACTT (shCav-1-(#3)),
GCTTCCTGATTGAGATTCAGT (shCav-1(#5)) and
CGCTGAGTACTTCGAA ATGTC (shLuc). ECCs (5×105)
were plated and transduced with the indicated shRNAs
and selected in puromycin-containing (1 μg/ml) cell cul-
ture medium for 1 week.
Western blotting
Cells were rinsed and harvested in ice-cold PBS contain-
ing 1 mM orthovanadate, 10 μg/ml benzamidine, 2 μg/
ml antipain, 1 μg/ml leupeptin and 1 mM phenylmethyl-
sulphonylfluoride (Ova-BAL-PMSF). Cells were centri-
fuged at 3000xg for 2 min at 4 °C and the respective cell
pellets were lyzed by sonication in extraction buffer
(Hepes 20 mM pH 7.4, NP40 0.1 % and SDS 0.1 % plus
Ova-BAL-PMSF). The protein concentration of cell ex-
tracts was determined using the BCA protein assay kit.
Cell extracts were separated by SDS-PAGE, transferred
to nitrocellulose, blocked in PBS containing 5 % non-fat
milk and probed overnight at 4 °C with the anti-CAV1
antibody (1:5000) diluted in PBS containing 5 % gelatin
and 1 % Tween-20. Equal loading per lane was assessedby probing with an anti-β-actin antibody (1:5000). Goat
anti-rabbit IgG antibodies coupled to horseradish perox-
idase antibodies were used to detect bound first anti-
bodies by EZ-ECL. Protein bands were quantified by
densitometric analysis using the ImageJ 1.34 s software
(available from NIH at http://imagej.nih.gov/ij/).Analysis of mRNA levels by real time RT-PCR
Total RNA was isolated with the reagent TriZOL® fol-
lowing instructions provided by the manufacturer. RNA
samples, characterized by electrophoresis in 1 % agarose
gels (quality control), were treated with RNAase-free
DNAase and employed as templates to generate cDNA
using M-MLV Reverse Transcriptase. Oligonucleotides
for CAV1 (sense primer 5′– TGGTTTTACCGCTT
GCTGTCTG-3′; anti-sense primer 5′– GCAAGTT
GATGCGGACA TTGCT-3′) and β-actin (sense primer
5′- TGG CAC CCA GCA CAA TGA AGA -3′; anti-
sense primer 5′- GAA GCA TTT GCG GTG GAC GAT
-3′) were designed using Mx-Pro – Mx3000P v4.10 soft-
ware (Stratagene, USA). Real-time PCR was performed
using the Stratagene Mx3000p Real-Time PCR System
with the Brilliant II SYBR Green Master Mix qPCR kit.
The reaction cycle consisted of a first stage for 10 min
at 95 °C followed by 40 cycles of consecutive 15-second
steps at 95 °C, 60 °C and 72 °C. Data were processed
using Stratagene MxPro software, based on the quantifi-
cation method described by Pfaffl, 2001 [30]. The results
are expressed as fold increases in CAV1 mRNA levels.Proliferation assay
Ishikawa and Hec-1A cells (3×103) were seeded in 96-
well plates and cultured for 24 h in normal medium.
Then, cells were serum starved for 24 or 48 h, respect-
ively, prior to 4β-TPA (100 nM) treatment. Cell prolif-
eration was evaluated using the MTS® Proliferation
Assay Kit.Anchorage independent growth
Ishikawa and Hec-1A cells (1,5×103/well) were sus-
pended in 0,5 mL DMEM-F12 containing 10 % FCS and
0,3 % low melting point (l.m.p) agarose (Invitrogen,
Carlsbad, USA). This low percentage agarose was poured
on top of a 0,5 mL solidified bottom layer containing
0,8 % l.m.p. agar in a 24-well plate, allowed to solidify at
room temperature and then returned to 37 °C. 4β-TPA
(100 nM) was added every two days. On days 6-8, plates
were photographed and the number of colonies in three
random fields was determined. Colony forming effi-
ciency was defined as the number of colonies per total
of cells seeded in the fields counted.
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Assays were performed in Boyden Chambers (Transwell
Costar, 6.5 mm diameter, 8 μm pore size) according to
the manufacturer’s instructions. Briefly, the bottom sides
of the inserts were coated with 2 μg/ml fibronectin.
1.5×104 cells were resuspended in serum-free medium
and plated on to the top of each chamber insert and
serum-free medium was added to the bottom chamber.
After 7.5 h, inserts were removed, washed and cells that
migrated to the lower side of the inserts were stained
with 0.1 % crystal violet in 2 % ethanol and counted in
an inverted microscope.
Matrigel invasion assay
Ishiwaka and Hec-1A cells (6×105) were seeded 24 h be-
fore serum deprivation for 24 or 48 h, respectively, and
2×105 cells were seeded over 8 μm-porous inserts cov-
ered with matrigel (Matrigel Invasion Chamber 8.0 μm,
BD Biosciences, Bedford , USA). 4β-TPA (100 nM) was
added for 24 h. The inserts were fixed in cold methanol
and presence of cytokeratin was detected by immuno-
cytochemistry using specific antibodies. The membranes
were mounted in Mowiol and observed under a light
microscope and at least 10 fields were evaluated (40×
magnification). The number of cells per field was
determined.
Statistical analysis
All data are expressed as mean ± standard error of mean
(SEM) of three indepentent experiments. Data were ana-
lyzed using the unparied t-test. All data were processed
using INSTAT v. 3.05 (GraphPad Software, San Diego,
USA, http://www.graphpad.com). Statistical significance
was established at the P < 0.05 level.
Results
Expression of CAV1 in human endometrial tissues
Samples from normal endometrial tissues and endomet-
rial adenocarcinomas were processed for detection of
CAV1 by immunohistochemistry (Fig. 1a and b). In nor-
mal proliferative endometrium (NPE), CAV1 was barely
detectable and predominantly present in the stroma. On
the contrary, in hyperplasia, which is characterized by
increased proliferation of the endometrial epithelial cells,
CAV1 expression was elevated in the glandular epithe-
lium and remained increased in the different stages of
endometrial tumor progression (grades 1-3; G1, G2 and
G3) compared to NPE (Fig. 1a and b). Quantification
and comparison of CAV1 expression in normal and
pathological epithelium showed that CAV1 levels were
significantly elevated in pre-cancerous stages of hyper-
plasia, as well as G1, G2 and G3 stages of endometrial
adenocarcinoma when compared to NPE (Fig. 1c). Alter-
natively, while CAV1 expression was readily appreciablein most endometrial tissues, caveolin-2 was barely de-
tectable (data not shown). This result associates elevated
caveolin-1 presence in the absence of caveolin-2 with
characteristics that may favor tumor progression. This
interpretation was subsequently confirmed by observa-
tions in vitro using endometrial cancer cells (ECC).
12-O-tetradecanoyl-phorbol-13-acetate (4β − TPA)
increased CAV1 mRNA and protein levels in Ishikawa and
Hec-1A cells
Expression of CAV1 was analyzed in Ishikawa and Hec-
1A cells. Both cell lines expressed CAV1 mRNA and pro-
tein, whereby the less differenciated Hec-1A, was found to
express more CAV1 mRNA and protein than Ishikawa
(data not shown). Thus, CAV1 expression levels correlated
inversely with the differentiation status of ECC lines. To
study the potential role of this protein in ECC, we first
evaluated whether treatment with 4β-TPA, augmented
CAV1 levels in Ishikawa and Hec-1A cells (Figs. 2 and 3).
Because endogenous CAV1 levels were elevated in both
cell lines, we evaluated whether basal CAV1 levels could
be decreased by serum starvation. The absence of serum
was beneficial for subsequent experiments evaluating mi-
gration and invasion, because contributions of prolifera-
tion to the results observed were essentially eliminated by
this proceedure. Indeed, the changes were greater for Ishi-
kawa and Hec-1A cells after 24 and 48 h of starvation, re-
spectively (Additional file 1: Figure S1). Treatment with
4β −TPA increased CAV1 mRNA in serum-starved Ishi-
kawa (Fig. 2a) and Hec-1A (Fig. 2b) cells compared with
non-treated, control cells. Likewise, also CAV1 protein
levels increased in 4β −TPA treated Ishikawa and Hec-1A
cells (Fig. 3a and b, respectively). Hence, the tumor pro-
moting agent 4β −TPA augmented CAV1 expression in
human endometrial adenocarcinoma cells.
In subsequent experiments, CAV1 was down-regulated
in ECC by transducing these cells with lentivirus encod-
ing short harpin RNAs specific for CAV1 (shCav-1). As
anticipated, CAV1 mRNA and protein levels decreased
following lentivirus-mediated transduction, particularly
when using the shRNA Cav-1(#5) in both Ishikawa
(Figs. 2a and 3a) and Hec-1A (Figs. 2b and 3b) cells.
Moreover, 4β-TPA was unable to up-regulate CAV1 in
shRNA Cav-1(#5) Ishikawa or Hec-1A cells (Figs. 2 and
3). Finally, in Ishikawa and Hec-1A cells transfected with
the shLuc control construct, slightly elevated basal
CAV1 levels were observed. Nonetheless, addition of
4β-TPA increased CAV1 mRNA and protein levels sig-
nificantly (Figs. 2 and 3). Here, it should be noted that
similar results were obtained with an alternative short
hairpin construct, shRNA Cav-1(#3), although effi-
ciency was lower (Additional file 2: Figure S2). For this
reason, shRNA Cav-1(#5) and shLuc control cells were
compared in subsequent experiments.
Fig. 1 Expression of CAV1 in human normal and pathological endometrial tissues. a: CAV1 protein was detected in immunohistochemical sections as
described. Representative results shown for non-cancerous endometrium (a) include normal proliferative endometrium (NPE, n = 3) and endometrial
hyperplasia (EH, n = 4). A negative control (without primary antibody) from a endometrial tumor grade III sample is included (NC). Results obtained
with endometrial tumors grade I (G1, n = 3), grade II (G2, n = 3) or grade III (G3, n = 3) are also shown (b). Magnification bar, 50 μm. Boxed areas
highlighted in the upper panels are shown at a higher magnification (Magnification bar, 300 μm) in the lower panels. c: Specific CAV1 staining was
quantified using the ImagePro Plus software (Media Cybernetics, Bethesda, MD, USA). Only epithelial cells were included in this analysis. The Expression
Level Score (% ELS) was determined based on averaged optical density and the corresponding area. Statistically significant differences compared to PE
using an unpaired t-test are indicated (*, p < 0.05; **, p < 0.01)
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CAV1 in ECC
Because CAV1 was suggested to favor cell proliferation
in breast cancer cells [13], we evaluated whether alter-
ations in CAV1 levels affected proliferation in Ishikawaand Hec-1A cells transduced with the shCav-1(#5) or
shLuc contructs. First, shLuc and shCav-1(#5) Ishikawa
or Hec-1A cells were seeded in the presence of serum
for 24 h and then serum-starved for 24 or 48 h, respect-
ively, prior to evaluating cell proliferation. No differences
Fig. 2 CAV1 mRNA levels increased in ECC after exposure to 4β-TPA.
Ishikawa and Hec-1A cells were transduced with CAV1 shRNA (shRNA
Cav-1-(#5)) or shRNA for Luciferase (shLuc), as a control. Stably
transduced cells expressing the corresponding construct were
obtained by selection in medium with puromycin. Wild type or
transduced Ishikawa (a) and Hec-1A (b) cells were seeded in 6-cm
dishes for 24 h in complete medium and then cultured in medium
without serum for 24 h or 48 h, respectively, prior to 100 nM 4β-
TPA stimulation for 24 h. CAV1 mRNA levels were assessed by real
time RT-PCR analysis. β-actin was used as an internal control.
Values obtained by analysis of three independent experiments are
shown for CAV1 mRNA following standardization to β-actin (mean
± SEM). Data were analyzed using the unparied t-test. Statistically
significant differences compared with the controls are indicated
(*, p < 0.05, **,p < 0.01). Note that levels detected for the wild type
(WT) cells without 4β-TPA were assigned the reference value 1
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tranduced Ishikawa cells compared to the control shLuc
cells in the absence of 4β-TPA, although a trend towards
reduced proliferation was apparent; however, in the pres-
ence of 4β-TPA the previously detected trend became
signifcant (Fig. 4a). For shCav-1(#5) Hec-1A cells, a ten-
dency towards decreased proliferation was observedcompared with the control shLuc cells both in the ab-
sence and presence of 4β-TPA (Fig. 4b), although this
trend was never statistically significant. Taken together,
these results suggest that CAV1 presence in the absence
of 4β-TPA does not modulate ECC proliferation. Here, it
should be noted that 4β-TPA was also unable to stimu-
late significantly proliferation of wild-type cells (Fig. 4a
and b).
CAV1 expression in ECC favored anchorage-independent
growth
Anchorage-independent growth in vitro in soft agar is
thought to reflect the capacity of cells to establish tu-
mors in vivo. Hence, the ability of 4β-TPA to promote
colony formation in soft agar of Ishikawa and Hec-1A
cells, transduced with either shLuc or shRNA Cav-1(#5),
was tested (Fig. 5). In the absence of 4β-TPA, shLuc
Ishikawa and Hec-1A cells formed colonies and this abil-
ity was reduced in shRNA Cav-1(#5) cells (Fig. 5a and b,
respectively). Interestingly, the presence of 4β-TPA
slightly enhanced colony formation only in shLuc Hec-
1A, but not in shLuc Ishikawa cells. However, shRNA
Cav-1(#5) cells decreased colony formation efficiency in
the two cell lines, both in the absence or presence of
4β-TPA, thereby implicating CAV1 in promoting
anchorage-independent growth in ECC.
CAV1 expression in ECC augmented transmigraton and
invasion
Because the ability to migrate and permeate the extracel-
lular matrix are important events in cancer metastasis,
we then evaluated the effect of 4β-TPA-mediated up-
regulation of CAV1 in transmigration assays in the ab-
sence of serum. To that end, the transduced Ishikawa
and Hec-1A cells were cultured without serum 24 or
48 h prior to treatment with 100 nM 4β-TPA. As ex-
pected, migration was substantially increased after 4β-
TPA stimulation in shLuc Ishikawa and shLuc Hec-1A
cells in comparison with the non-treated cells (Figs. 6a
and b). Moreover, this effect was not seen in shRNA
Cav-1(#5) Ishikawa and Hec-1A cells (Figs. 6a and b). It
should be noted again that similar results to those re-
ported here for shCav-1(#5) were obtained with shCav-
1(#3) cells (Supplementary Fig. 2c and d), in which
CAV1 knock-down was not as efficient (Supplementary
Fig. 2a and b). Thus, loss of CAV1 significantly reduced
the migration of both adenocarcinoma cell lines in the
absence or presence of 4β-TPA.
Down-regulation of CAV1 decreased matrigel invasion of
ECC
To assess whether increased CAV1 expression was
linked to invasion, the shLuc and shCav-1(#5) Ishikawa
and Hec-1A cells were evaluated in matrigel assays
Fig. 3 CAV1 expression increased in ECC after exposure to 4β-TPA.
Ishikawa and Hec-1A cells were transduced with CAV1 shRNA
(shRNA Cav-1-(#5)) or shRNA for Luciferase (shLuc), as a control.
Stably transduced cells expressing the corresponding construct
were obtained by selection in medium with puromycin. Wild type
and transduced Ishikawa (a) and Hec-1A (b) cells were seeded in
6-cm dishes for 24 h in complete medium and then cultured in
medium without serum for 24 h or 48 h, respectively, prior to 100
nM 4β-TPA stimulation for 24 h. CAV1 protein levels were determined
by Western blot analysis. β-actin was used as internal control. Values
obtained by scanning densitometric analysis of three independent
experiments are shown for CAV1 following standardization to β-actin
and normalization to shLuc cells without treatment (mean ± SEM).
Data were analized using the unpaired t-test. Statistically significant
differences compared with the controls are indicated (*, p < 0.05,
**,p < 0.01). Note that levels detected for the shLuc cells without 4β-
TPA were assigned the reference value 1
Fig. 4 Effects of CAV1 down-regulation on ECC proliferation. Wild type,
shLuc and shCav-1(#5) Ishikawa (a) and Hec-1A (b) cells were seeded
in complete medium in 96-well plates 24 h prior to serum withdrawal
for an additional 24 or 48 h of culture, respectively. After 24 h of 100
nM 4β-TPA treatment, cell proliferation was evaluated using the MTS®
assay according to the manufacturer’s instructions. Data averaged from
three independent experiments are shown (mean ± SEM). Statistically
significant differences compared with the control group (shLuc cells
without 4β-TPA, reference value 1 ) are indicated (*, p < 0.05)
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Fig. 5 CAV1 expression in ECC favored anchorage independent growth. Anchorage-independent growth was examined for shLuc or shCav-1(#5)
Ishikawa and Hec-1A cells in soft agar. Colony-forming efficiency (CFE) was determined as the number of colonies per total number of visible
cells. Statistically significant differences compared with the corresponding control group are indicated (**, p < 0.01, ***, p < 0.001). Ishikawa (a) and
Hec-1A (b) cells were treated with either 100 nM 4β-TPA in DMEM-F12 in the absence of serum for 6-8 days. shLuc Ishikawa or Hec-1A cells
without 4β-TPA were considered as the control groups (28 ± 4 or 22 ± 4 colonies, respectively)
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significantly enhanced the invasiveness of shLuc Ishi-
kawa and Hec-1A cells and that the invasive potential
was substantially reduced in cells expressing shRNA
Cav-1(#5). Thus, CAV1 expression in ECC is associated
with enhanced invasiveness in matrigel assays.
Taken together our results associate basal, as well as
4β-TPA-enhanced CAV1 expression in ECC with en-
hanced malignancy, as defined by increased anchorage-
independent growth, transmigration and matrigel
invasion.Discussion and conclusions
CAV1 is known to be upregulated in later stages of
many cancers, to enhance migration and invasion of
tumor cells of different origin, and to be associated with
poor patient prognosis. Whether this may be the case
for ECCs has not been determined. Here we show that
CAV1 was detected in cancerous epithelial cells of the
human endometrium at substantially elevated levels
compared with the normal proliferating epithelium. In
the human ECC lines Ishikawa and Hec-1A CAV1 was
also present. In addition, in both Ishikawa and Hec-1A
Fig. 6 CAV1 expression in ECC augmented transmigration and invasion. To evaluate the role of the up-regulation of CAV1 mediated by 4β-TPA in
transmigration 6 × 105 shLuc and shCav-1(#5) Ishikawa or Hec-1A cells were seeded in 6 cm plates in complete medium for 24 h prior to serum
withdrawal for an additional 24 or 48 h of culture, respectively. After 24 h of 100 nM 4β-TPA treatment 2 × 105 shLuc and shCav-1(#5) Ishikawa (a) or
Hec-1A (b) cells were seeded in Boyden Chambers coated on the lower side with fibronectin (2 μg/ml) and allowed to migrate in the absence of
serum for 7.5 h. The cells that migrated through the pores and bound to the lower fibronectin-coated surface were stained and counted. Values
obtained were normalized to the shLuc cells without treatment. The number of transmigrated shLuc cells observed in panels a and b were 48 ± 9 and
94 ± 26, respectively. Averages from three independent experiments are shown (mean ± SEM). Statistically significant differences compared with the
corresponding control group are indicated (*, p < 0.05). To evaluate the role of the up-regulation of CAV1 mediated by 4β-TPA in invasion, shLuc and
shCav-1(#5) Ishikawa and Hec-1A cells were seeded in 6 cm plates in complete medium 24 h prior serum withdrawal for an additional 24 or 48 h of
culture, respectively. After 24 h of 100 nM 4β-TPA treatment 2 × 105 shLuc and shCav-1(#5) Ishikawa (c) and Hec-1A (d) cells were seeded over matrigel
covered porous inserts, with or without 100 nM 4β-TPA for 24 h. The number of cells that invaded the matrigel and migrated through the pores were
determined after immunostaining for cytokeratin. Averages from three independent experiments are shown (mean ± SEM). Statistically significant
differences compared with the corresponding control group are indicated (*, p < 0.05, **, p < 0.01, ***, p < 0.001)
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creased CAV1 protein and mRNA levels. Importantly,
reduction of endogenous CAV1 expression using specific
shRNA constructs diminished ECC migration, invasion
and anchorage-independent growth. Thus, CAV1 ex-
pression is associated with enhanced maligancy of ECCs.
Several studies have shown that CAV1 expression de-
creases during the genesis of human tumors in tissues
such as lung, breast, colon and ovary. Additionally, re-
expression of CAV1 is sufficient to revert the transformed
phenotype of mammary [31], colon [6] and ovarian carcin-
oma cells [32]. These studies suggest that CAV1 may
function as a tumor suppressor protein, possibly by inhi-
biting signaling pathways aberrantly activated in cancer
cells and promoting cell death [25, 32].
Alternatively, CAV1 also promotes malignant charac-
teristics in cancer cells, like anchorage-independent
growth [33], cell proliferation [13], multi-drug resistance
[16, 17], cell polarization and migration [34–36] andmetastasis [8, 37]. Thus, the frequently observed initial
decrease in CAV1 expression appears to be a reversible
process, whereby increased expression of CAV1 at later
stages is then associated with elevated metastatic poten-
tial in colon [9], lung [38] and prostate cancer cells [39]
and with poor prognosis for prostate [7] or colon [9]
cancer patients. Taken together, these data indicate that
CAV1 function may change rather dramatically during
tumor progression [40, 41]. Interestingly, however, the
current study points towards a unique pattern of CAV1
expression in the human endometrium, because CAV1
levels were consistently elevated in all pathological
stages. Thus, although in this tissue elevated CAV1 ex-
pression appears relevant to tumor development, it can-
not per se be associated with tumor progression in
endometrial cancer patients and additional factors must
be invoked to explain how CAV1 presence may favor
traits associated with a more aggressive phenotype in
ECC.
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mRNA and protein levels reportedly increase with the
passage number of CHEC cells and morphological
changes characteristic of EMT [21]. However, in the
same study CAV1 expression in the highly differentiated
Ishikawa cell line was significantly lower than in CHEC
cells derived from a stage I grade III endometrial adeno-
carcinoma, underscoring that the relationship between
CAV1 expression and tumor progression is complex.
Indeed, our results corroborate this notion, because CAV1
presence enhanced malignancy of ECC, yet protein levels
were lower in Ishikawa than in the moderately differenti-
ated Hec-1A cells.
Phorbol esters like 4β-TPA are known activators of
PKCs that promote tumor formation in two stage cancer
models in mice [23]. Although, they have been shown to
increase CAV1 expression in human lung fibroblast cells
[42], the possibility that phorbol ester induced tumor
promotion may be linked to changes in CAV1 has not
been previously considered. Here we observed in ECC
that 4β-TPA treatment increased CAV1 expression.
Moreover, elevated CAV1 levels in these cells augmented
invasive capacity/migration and anchorage-independent
growth in vitro, characteristics associated with more ag-
gressive tumor cell behavior in vivo. Hence, CAV1 pres-
ence in ECC favors the malignant tumor cell phenotype
and elevated expression in response to phorbol esters is
associated with tumor promotion in these cells.
Here it should be noted that 4β −TPA triggers inflam-
matory responses by increasing the expression of COX-2
through PKCα dependent pathways [43]. Interestingly,
our preliminary immuno-histochemical analysis identi-
fied substantial levels of PKCα both in normal and dis-
eased tissue samples (data not shown). However, levels
did not vary as a consequence of disease (data not
shown). Clearly, further experiments are required to de-
termine to what extent PKCα is involved in regulating
CAV1 expression. This possibility merits further consid-
eration, given that both PKCα and CAV1 have been in-
dependently associated with increased proliferation/
survival and migration/invasion phenotypes in certain
cancer cells [44, 45]
In summary, this study analyzes for the first time
CAV1 expression in the normal endometrial epithelium
and adenocarcinoma cells. Basal CAV1 expression, as
well as tumor promotor 4β −TPA induced CAV1 up-
regulation in endometrial adenocarcinoma cells were
linked to enhanced ECC malignancy. Thus, while
elevated CAV1 levels per se cannot be interpreted as a
marker of tumor progression because no significant
differences in protein levels were detected when compar-
ing tissue samples from stages I, II and III, the presence
of this protein in ECC clearly favored traits associated
with a more malignant phenotype.Additional files
Additional file 1: Figure S1. CAV1 protein levels in ECC after treatment
with 4β-TPA in the presence or absence of serum. Ishikawa (A) and
Hec-1A (B) cells were seeded in 6-cm dishes for 24 h in complete
medium and then cultured in the absence or presence of 4β-TPA (100
nM) (Lanes 1 and 2, respectively) or were cultured in medium without
serum for 24 h (Ishikawa) or 48 h (Hec-1A) and subsequently in the
presence or absence of 4β-TPA (Lanes 3 and 4, respectively). CAV1
protein levels were determined by Western blot analysis. β-Actin was
used as an internal control.
Additional file 2: Figure S2. CAV1 silencing in ECC inhibits 4β-TPA-
enhanced cell migration. Ishikawa and Hec-1A cells were transduced with
CAV1 shRNA (shRNA Cav-1(#3) or shRNAfor luciferase (shLuc), as a control.
Stably transduced cells expressing the corresponding construct were
obtained by selection in medium with puromycin. Transduced Ishikawa
(A) and Hec-1A (B) cells were seeded in 6-cm dishes for 24 h in complete
medium and then cultured in medium without serum for 24 h or 48 h,
respectively, prior to 4β-TPA (100 nM) stimulation for 24 h. CAV1 protein
levels were determined by Western blot analysis. β-Actin was used as an
internal control. 6×105 shLuc and shCav-1(#3) Ishikawa or Hec-1A cells
were seeded in 6-cm plates in complete medium for 24 h prior to serum
withdrawal for an additional 24 or 48 h of culture, respectively. After 24 h
of treatment with 4β-TPA (100 nM) , 2×105 shLuc and shCav-1(#3) Ishi-
kawa (C) or Hec-1A (D) cells were seeded in Boyden chambers coated
with fibronectin (2 μg/ml) and allowed to migrate in the absence of
serum for 7.5 h. The cells that migrated through the pores were stained
and counted. Values obtained were normalized to the shLuc cells without
treatment. Data averaged from two independent experiments are shown.
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